Chapter 1. Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview

  1. Peter P. Toth M.D., PH.D. Director of Preventive Cardiology Chief of Medicine Clinical Associate Professor1,2,3,4 and
  2. Kevin C. Maki PH.D. President Chief Science Officer5

Published Online: 1 OCT 2008

DOI: 10.1002/9780470696873.ch1

Practical Lipid Management: Concepts and Controversies

Practical Lipid Management: Concepts and Controversies

How to Cite

Toth, P. P. and Maki, K. C. (2008) Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview , in Practical Lipid Management: Concepts and Controversies, John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470696873.ch1

Author Information

  1. 1

    Sterling Rock Falls Clinic, Ltd., USA

  2. 2

    CGH Medical Center Sterling, Illinois, USA

  3. 3

    Departments of Family and Community Medicine, University of Illinois College of Medicine Peoria, Illinois, USA

  4. 4

    Southern Illinois University School of Medicine, Springfield, Illinois, USA

  5. 5

    Provident Clinical Research & Consulting, Inc., Glen Ellyn, Illinois and Bloomington, Indiana, USA

Publication History

  1. Published Online: 1 OCT 2008
  2. Published Print: 17 OCT 2008

ISBN Information

Print ISBN: 9780470056905

Online ISBN: 9780470696873

SEARCH

Keywords:

  • lipid epidemiology and lipid management;
  • Framingham Heart Study;
  • cardiovascular epidemiology;
  • LDL-C and CHD risk;
  • low -density lipoprotein cholesterol (LDC-C);
  • LDL-C lowering and CHD risk reduction;
  • HDL-C and CHD risk;
  • national cholesterol education program (NCEP);
  • Apo B or LDL-P response in treatment

Summary

This chapter contains sections titled:

  • Early History of Cardiovascular Epidemiology

  • Lipid Risk Factors are Central to Efforts at CHD Prevention

  • LDL-C and CHD Risk

  • LDL-C Lowering and CHD Risk Reduction

  • Other Atherogenic Lipoproteins: Atherogenic Remnants

  • HDL-C and CHD Risk

  • Trends in Lipids and Lipid Management in the USA

  • The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II Survey

  • Controversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?